FalconX Raises $210M Following 30x YoY Revenue Growth; Now Valued at $3.75 Billion
10.8.2021 18:00:00 EEST | Business Wire | Press release
FalconX, a digital assets and cryptocurrency financial services company that provides institutions trading, credit, and clearing across major cryptocurrencies, announced a $210M Series C financing round, valuing the company at $3.75 billion. The round was led by Altimeter Capital, Sapphire Ventures and existing investors B Capital Group and Tiger Global Management, with participation from Mirae Asset. Amex Ventures also increased its existing investment as part of this round. They join existing investors Accel, Accomplice VC, Coinbase Ventures, CMT Digital, Flybridge Capital Partners, Lightspeed Venture Partners, and Avon Ventures, a venture capital fund affiliated with FMR LLC, the parent company of Fidelity Investments.
In just three years, FalconX has become one of the most highly valued institutional cryptocurrency companies in the world, driven by strong unit economics, profitability, and revenue growth across business lines. FalconX leverages machine learning to provide institutions a single counterparty with access to global cryptocurrency liquidity with 99.9%+ uptime through its web interface, APIs, and 24/7/365 white glove trading desk. Its credit business enables institutions to access short term financing for trades – filling the gap between long term loans and derivatives markets for institutions looking to increase their balance sheet efficiency in an elastic manner. FalconX plans to officially announce several new product offerings in the coming months, each of which are currently live, growing quickly, and profitable.
“FalconX is the trusted one-stop-shop for the world’s leading institutional cryptocurrency market participants – providing the technology, security, and reliability necessary to power their strategies at scale,” said Raghu Yarlagadda, CEO and Co-Founder of FalconX. “Serving the world’s leading investors, we are at the forefront of a megatrend which will fundamentally change financial services – if you wouldn’t accept Google or Amazon only working 5 days a week – why aren’t financial services 24/7, truly global, and more accessible? Blockchain has proven that it is possible at scale, and FalconX is excited to lead that change.”
FalconX’s growth is driven by demand from a diverse range of institutional market participants, including some of the world’s largest financial institutions, hedge funds, asset managers, venture capital firms, payment providers and investment applications – for secure, reliable, and bespoke cryptocurrency products. FalconX will use the funding from the Series C round to expand its product lines, explore strategic acquisitions, and continue to hire great talent globally, including key executives with backgrounds at the convergence of traditional financial markets, digital assets and technology.
Quotes on the Round :
“FalconX has clearly positioned itself as a leading institutional cryptocurrency company – we’re excited to back a market leader in an industry in the early innings of strong secular growth. FalconX’s product velocity and pace of innovation is remarkable and we believe will play an important role in the future of financial and crypto market infrastructure.” - Brad Gerstner, Founder & CEO, Altimeter Capital
“FalconX is recognized as a best-in-class institutional platform for cryptocurrency that facilitates billions in crypto trading each month. We have repeatedly heard institutional customers praise FalconX for their unmatched reliability and a one-stop-shop infrastructure platform to meet all their long-term crypto trading needs. We’re excited to partner with the FalconX team to build the de-facto platform that powers global discovery, exchange and transfer of all digital assets worldwide.” - Rashmi Gopinath, General Partner, B Capital Group
“FalconX has delivered strong business growth while building a world-class team that brings together talent from Silicon Valley, traditional financial markets and the blockchain ecosystem. This team is uniquely positioned to partner with its customers to create winning strategies and deliver new products that help them find scale.” - Rajeev Dham, Partner, Sapphire Ventures
“As institutional investors continue entering the cryptocurrency market, FalconX has significantly scaled its business and product lines to meet their needs. We’re excited to double down on the leading one-stop-shop for institutional trading, credit and clearing.” - Scott Shleifer, Partner, Tiger Global Management
About FalconX
FalconX is an all-in-one cryptocurrency and digital assets financial services platform facilitating trading, credit, and clearing for institutions. The company is backed by Accel, Accomplice VC, Altimeter Capital, B Capital Group, American Express Ventures, CMT Digital, Coinbase Ventures, Flybridge Capital Partners, Lightspeed Venture Partners, Mirae Asset, Sapphire Ventures, Tiger Global Management and Avon Ventures, a venture capital fund affiliated with FMR LLC, the parent company of Fidelity Investments. FalconX has offices in Silicon Valley, Chicago, Bengaluru, and Malta. For more information visit falconx.io.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210810005701/en/
Contact information
FalconX
Kelsey Williams
falconx@strangebrewstrategies.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 14:00:00 EEST | Press release
CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which was confirmed by the study’s independent DSMB (Data and Safety Monit
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint ® and BluePrint ® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 14:00:00 EEST | Press release
Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors – a group that typically has favorable outcomes. MammaPrint (MP) identified a High Risk 2 (H2) subset, representing 10% of all patients and 5% of those
The Biggest Predictor of Business Growth Is Behavior30.4.2026 10:00:00 EEST | Press release
IDEO, the global design and innovation company, today announced the IDEO Innovation Quotient (IDEO IQ), a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. Those with the highest IDEO IQ scores earned nearly $20 billion in profit last year—50% higher than average and three times more than those ranked at the bottom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429978890/en/ The IDEO Innovation Quotient (IDEO IQ) is a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. The IDEO IQ surveyed 266 leaders in product and innovation roles at 100 of the world’s largest companies across the Media & Technology, Healthcare, and Consumer Goods sectors. The report is the first of its kind to draw a direct line between how companies operate internally and their financial performance. Companies were surve
Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 01:22:00 EEST | Press release
Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste
The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 23:30:00 EEST | Press release
The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new phase, shaped by the convergence of procedures, longevity and b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom